华大基因：在肿瘤早筛领域公司近年来持续加大产品研发与市场推广力度

Core Viewpoint - The company has made significant progress in the field of early cancer screening, particularly in colorectal cancer, by enhancing product development and market promotion efforts [1] Group 1: Product Development and Market Expansion - The company has completed over 2.35 million fecal DNA methylation tests as of the reporting period [1] - New colorectal cancer prevention projects have been launched in multiple cities, including Qingdao and Shijiazhuang, with expectations for increased testing volumes starting in Q3 [1] - The screening scope has been expanded to include gastric cancer, liver cancer, and endometrial cancer, with related testing services being rolled out and qualification application plans in place [1] Group 2: Regulatory and Technical Innovation - Recent guidelines from national authorities on cancer early screening technologies provide clear direction and policy support for the industry [1] - The company is responding to regulatory requirements by accelerating product compliance and qualification layout, leveraging its technological advantages [1] - The developed non-invasive tumor characteristic screening technology is applicable for both screening scenarios and post-operative monitoring, allowing for multidimensional precise assessment of ctDNA status and dynamic changes [1]